Acquisition leverage Xcelience has been acquired by Capsugel, presenting an opportunity to align cross-sell with Capsugel’s broader capsule and formulation capabilities to existing clients and potential new customers seeking end-to-end dosage form solutions.

Contract manufacturing Operating as a small to mid-size unit with 11-50 employees, Xcelience can offer nimble, specialized manufacturing services for niche or early-stage biopharma and consumer health projects that require focused attention and rapid turnaround.

Capsugel synergy Leverage Capsugel’s established relationships and extensive capsule polymer science expertise to upsell advanced capsule-based formulations, bioavailability optimization, and customized packaging to current clients and new prospects.

Revenue growth Current revenue range ($25M–$50M) signals a scalable business with room for expansion via expanded service offerings, geographic outreach, and collaboration on high-value dosage forms across regulatory environments.

Market positioning Xcelience’s strengths in formulation know-how and process design can be highlighted to target biopharma and consumer health segments seeking rapid development timelines, enabling faster time-to-market and competitive differentiation.